Email updates

Keep up to date with the latest news and content from Biology of Mood & Anxiety Disorders and BioMed Central.

Open Access Correction

Correction: Somatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS

Cristina Cusin* and Darin D Dougherty

Author Affiliations

Division of Neurotherapeutics, Department of Psychiatry, Massachusetts General Hospital, 149 13th Street, Rm 2612, Charlestown, MA, 02129, USA

For all author emails, please log on.

Biology of Mood & Anxiety Disorders 2013, 3:1  doi:10.1186/2045-5380-3-1

Published: 1 January 2013

First paragraph (this article has no abstract)

Since the initial publication of the review article [1], a number of readers have contacted us to clarify potential erroneous information in the article. These comments focused on our review of the use of transcranial magnetic stimulation (TMS) for treatment-resistant depression (TRD). In the initial article, we concluded that TMS is well-tolerated and has been approved by the FDA for adults who have failed to respond to one antidepressant, but that its use in TRD was not yet supported by rigorous double-blind randomized clinical trials. It should be noted, that for the article, we searched PubMed and based our review on the several meta-analyses we found during this search.